Asymmetrical Bioimpedance in the Anterior Circulation for Urgent Stratification of suspected Stroke (ABACUS Stroke): study protocol for a diagnostic accuracy study by Price CI et al.
PROTOCOL Open Access
Asymmetrical Bioimpedance in the Anterior
Circulation for Urgent Stratification of
suspected Stroke (ABACUS Stroke): study
protocol for a diagnostic accuracy study
Christopher I. Price1*, Lisa Shaw1* , Anand Dixit2, Sara Graziadio3, Clare Lendrem3, Dipayan Mitra2,
Helen Rodgers1,2, Lou Sutcliffe1 and Phil White1,2
Abstract
Background: Early identification and treatment of stroke improve outcome. Ischaemic stroke due to large vessel
occlusion (LVO) benefits from time-critical thrombectomy but this is only available in highly specialised healthcare
services. Cerebral Bioimpedance Asymmetry (CBA) measurement obtained with the portable and rapid Cerebrotech
Visor™ System device may be able to identify certain types of stroke including LVO. This test could be deployed
pre-hospital and used to immediately direct patients to the most appropriate healthcare service for treatment. This
study is evaluating the diagnostic accuracy of CBA measurements obtained from a real-world population of suspected
stroke.
Methods: Study design: Prospective observational cohort study.
Setting: A hyperacute stroke unit and neuroscience centre in North East England.
Participants: Adults with a paramedic assigned diagnosis of suspected stroke arriving at hospital within 6 hours of
symptom onset.
Index Test: Cerebral Bioimpedance Asymmetry measurement performed using the Cerebrotech Visor™ System.
Measurement values produce continuous data (range 0 –100); pre-defined threshold for positive state ≥ 10.
Reference Standard Tests: Standard CT brain +/- CT/MR angiography, and expert clinician opinion will establish the
following clinical outcomes which constitute the suspected stroke population: ischaemic stroke +/- large vessel
occlusion; symptomatic severe anterior vessel stenosis; large (≥60ml) and small (<60mls) vessel intracerebral
haemorrhage; transient ischaemic attack; stroke mimic conditions; prior territorial stroke.
Analyses: Sensitivity, specificity, negative and positive predictive values, area under the Receiver Operating
Characteristic curve for identification of i) “complex stroke” (ischaemic stroke with large vessel occlusion or
symptomatic severe anterior vessel stenosis or intracerebral haemorrhage ≥60ml or prior territorial stroke) and ii)
ischaemic stroke with large vessel occlusion in isolation.
Sample size: 124 participants
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Discussion: The results from this study will determine how accurately CBA measurement using the Cerebrotech Visor™
System can identify key stroke types within the suspected stroke population. Acceptable diagnostic performance
would be an important step forwards for access to time-critical treatments.
Trial registration: Registered with ISRCTN (identifier: ISRCTN79169844) on 06/08/2018.
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Background
Stroke is responsible for a high global burden of mortality
and disability which is likely to increase in line with the
ageing population [1]. It is a common medical emergency
and in the UK, there are 86,000 admissions per year with
an economic impact of £9 billion in health and social care
costs [2]. The cause of stroke is either cerebral ischaemia
(85%) or haemorrhage (15%) and although all patients
benefit from urgent admission to organised multidisciplin-
ary stroke care [3], there is strong evidence that two emer-
gency reperfusion treatments for ischaemic stroke
significantly reduce long-term disability: intravenous
thrombolysis (up to 15% patients: mean number needed to
treat 7) [4, 5] and intra-arterial mechanical thrombectomy
(up to 10% patients: mean number needed to treat 3) [6].
The latter is an effective minimally invasive surgical treat-
ment during which an interventional neuro-radiologist ex-
tracts thrombus causing large vessel occlusion (LVO).
To achieve optimal benefit, thrombectomy must be
performed as soon as possible for patients with
moderate-severe clinical stroke severity (National Insti-
tutes for Health Stroke Score (NIHSS) [7] > 5 points),
and within 6 h of stroke onset according to current clin-
ical guidelines [8, 9], although evidence continues to
emerge of later benefit [6, 10]. Without treatment, these
patients have a poor outcome because a large clot causes
a reduction in blood supply to most of one cerebral
hemisphere, and thrombolysis alone is less likely to re-
store independence [11, 12].
Thrombectomy provision is currently expanding in
many countries. In the UK, regional neuroscience ‘hubs’
will provide this treatment for populations of 1.5–3
million. The majority of eligible patients will initially be
identified at local Hyperacute Stroke Units (HASU)
‘spokes’ which serve populations of 0.3–1 million. Due
to the expertise and facilities required, thrombectomy
cannot be provided at every HASU and will only be
available in 25 out of 126 sites admitting stroke across
England, Wales and Northern Ireland [13]. In this ser-
vice arrangement, patients presenting at local HASU’s
with ischaemic stroke that appear potentially suitable
for thombectomy on the basis of clinical stroke severity
(NIHSS > 5), radiological criteria and previous medical
history will need to undergo additional local CT
angiography or MR angiography to confirm the pres-
ence of LVO before transfer onto the regional neurosci-
ence hub. This assessment process takes at least one
additional hour relative to direct admission to a re-
gional neuroscience hub [14]. In addition, CT/MR angi-
ography is not yet routinely available at all local HASUs
in the NHS, and patients admitted to these sites may
not be offered thrombectomy treatment as LVO cannot
be identified.
Thrombectomy treatment rate and speed would be
much improved if patients with LVO stroke could be
identified sooner. If this could be done in ambulances, it
would enable transportation directly to a regional neuro-
science centre. However, reducing the need for add-
itional CT/MR angiography at a local HASU would also
be of benefit. In terms of pre-hospital detection of LVO,
paramedic completed clinical assessments have been de-
veloped to identify LVO stroke patients, but their per-
formance in practice does not support widespread
introduction [15].
Whereas there would be global agreement that early
recognition of patients with a high probability of LVO
could improve thrombectomy outcomes, internationally
there are also variations in stroke service provision which
impact more broadly upon optimal stratification of pa-
tients with stroke. In the UK, there is an expectation that
all stroke patients are routinely admitted to a HASU pro-
viding specialist multidisciplinary care irrespective of
severity or aetiology, and following initial assessment, only
a small number are escalated to regional neuroscience
centres for specific medical treatments such as thrombec-
tomy. Due to the organisation of healthcare delivery in
other nations, there is often greater reliance upon individ-
ual clinical need when deciding upon the immediate care
destination, i.e. those cases that may require complex as-
sessment and/or treatment are identified for early escal-
ation beyond the first admitting hospital (which may not
have a HASU), whereas patients with uncomplicated
minor stroke may remain under the most appropriate
local speciality. Early identification of this ‘complex’ group
could also improve outcomes and resource utilisation in
these healthcare systems.
More complex scenarios include symptomatic severe
anterior vessel stenosis (SSAVS) of the internal carotid
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or middle cerebral arteries, large volume intracerebral
haemorrhage and patients with a prior territorial stroke
(PTS). In SSAVS, although the reduced cerebral perfu-
sion is not due to an occluding thrombus, the clinical
presentation of these patients is similar, and they may
require advanced neuroimaging and an experienced clin-
ical opinion to determine whether urgent stenting
should be offered on a case by case basis [16]. Large vol-
ume (≥ 60 ml) intracerebral haemorrhage (LICH) is as-
sociated with high morbidity and mortality [17], but
early identification could improve outcomes through
physiological monitoring, blood pressure control, rever-
sal of coagulopathy, neurosurgical review and advanced
imaging to prevent early recurrence [18]. Patients with a
prior territorial stroke are at higher risk of further events
and early complications, and their immediate manage-
ment is more likely to require advanced imaging, experi-
enced clinical opinion and decision making, and expert
multidisciplinary input.
The recently developed Cerebrotech Visor™ System
(CVS) uses the principles of volumetric integral phase-
shift spectroscopy to measure and compare alterations in
electrical properties of brain tissue (cerebral bioimpe-
dance) resulting from changes in fluids [19, 20]. Low-
power electromagnetic waves are transmitted through the
brain at multiple frequencies towards a receiver. The
phase shifts and attenuations between the transmitter and
receiver are sensitive indicators of alterations in brain
fluids and can compare fluid changes between cerebral
hemispheres providing a measurement of Cerebral Bioim-
pedance Asymmetry (CBA). The CVS is worn like
spectacles over the forehead; it is portable and measure-
ment takes approximately 3 min.
Preliminary data from using the CVS in a hospital set-
ting suggest that most cases of ‘complex stroke’ (defined
as ischaemic stroke with LVO, or SSAVS or LICH with
≥ 60 ml haematoma volume, or PTS) can be identified
by CBA measurement. A retrospective analysis was able
to distinguish between 57 cases of complex stroke and
26 cases of ‘minor stroke’ (defined as ischaemic stroke
without LVO or ICH < 60 ml haematoma volume) with
93% (95% CI: 83–98) sensitivity and 92% (95% CI: 75–
99) specificity at the optimum CBA threshold [21]. The
area under the receiver operating characteristic curve
was 93%. Most of the complex stroke cases were ischae-
mic stroke due to acute LVO (n = 41).
Although these preliminary data are encouraging, the
patients included were already identified by medical staff
as ‘likely stroke’ and as such were not representative of
all patients with suspected stroke seen by pre-hospital
clinicians or arriving at a HASU. Currently, in the UK,
30–40% of emergency ambulance admissions with sus-
pected stroke are later diagnosed with a stroke ‘mimic’
condition such as seizure or migraine [22]. To be of
optimal benefit, the CVS would need to identify patients
with complex stroke from within a broad population of
suspected stroke.
This manuscript describes the protocol for a study to
evaluate the CVS diagnostic performance in a population
of unselected suspected stroke arriving at a UK HASU.
Whilst the most important future use for the CVS is likely
to be in the pre-hospital setting, conducting research eval-
uations in this context is particularly challenging and prior
to embarking on such a study, there needs to be prelimin-
ary data of accuracy in a comparable population. This can
be achieved by obtaining CBA readings undertaken by
trained hospital staff from patients with a paramedic
assigned diagnosis of suspected stroke immediately follow-
ing hospital admission and before specialist or radiological
diagnosis is made. This research is timely and topical be-
cause finding an accurate, portable and potentially widely
available point of care diagnostic for LVO or complex
stroke would revolutionise stroke care.
Methods
Study objectives
 To determine the diagnostic accuracy of CBA
measurement performed using the CVS to identify
complex stroke (ischaemic stroke with LVO or
SSAVS or LICH ≥ 60 ml in volume or PTS) in
patients arriving at a hospital with a paramedic
assigned diagnosis of suspected acute stroke.
 To determine the diagnostic accuracy of CBA
measurement performed using the CVS to identify
LVO in patients arriving at a hospital with a
paramedic assigned diagnosis of suspected acute
stroke.
 To explore key clinical and radiological influences
upon the diagnostic accuracy of CBA measurement
for complex stroke and LVO.
 To report the technical failure rate of the CVS.
Study design
The study design is a prospective blinded observational co-
hort study. Participants will undergo CBA measurement with
the CVS but otherwise will receive standard care and investi-
gations as per current local ambulance and hospital clinical
protocols, which are underpinned by national clinical guide-
lines [8] and audit [13]. The CVS does not display the CBA
result which must be generated from raw reading data by
the manufacturer. The CBA reading will not be available to
participants or any clinical staff involved in routine care.
Similarly, clinical data will not be available to the manufac-
turer prior to the provision of a CBA reading to researchers.
There will be no change to participant treatment as a result
of the study.
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The study will be reported according to the STARD
guidelines (Standards for the Reporting of Diagnostic ac-
curacy studies) [23].
Study setting
The study will take place within a single site (Royal
Victoria Infirmary, Newcastle upon Tyne, UK) which re-
ceives approximately 1500 direct ambulance admissions of
patients with suspected stroke annually. This is a regional
neuroscience centre providing thrombectomy within 6 h
of symptom onset for patients with an NIHSS > 5 points
and LVO proven by CT angiography. Patients will be
assessed in the HASU and emergency department.
Study participants
Trained hospital staff (e.g. research nurses, research
trained doctors) will attempt a CBA measurement with
the CVS on patients that fulfil the following criteria:
Inclusion criteria:
 Aged 18 years or over
 Transportation to the study hospital by ambulance
 New stroke suspected by ambulance personnel
before hospital arrival
 At least responsive to tactile stimuli on hospital
arrival—i.e. A, V or P on the Alert Voice Pain
Unresponsive (AVPU) scale.
 Routine emergency brain imaging is intended to be
performed within 60 min of hospital arrival or has
already been performed within 60 min of hospital
arrival
 A CBA reading can be attempted +/− 30 min of the
first routine emergency brain imaging
 The CBA reading can be attempted within 6 h of a
hospital stroke specialist last known well time or
symptom onset time.
Exclusion criteria:
 Females who are pregnant, lactating or at risk of
pregnancy (i.e. who are not surgically sterile or at
least 1 year post last menstrual period). If this
information is unknown/cannot be rapidly
established, females < 56 years of age will be
excluded.
 Already assessed at another hospital and transfer to
the regional neurosciences centre is for further
investigation or treatment
 Hypoglycaemia (capillary glucose < 3.5 mmol/l)
 Presence of any known implanted electro-
stimulating devices in the head and neck
 Presence of implanted hearing aids (removable
hearing aids should be taken out before use of the
CVS)
 Presence of any known metallic craniofacial
implants, such as bone fixation plates (aneurysm
coils or clips are acceptable) or cranioplasty
 Recent craniotomy, craniectomy or other reason
known for the presence of intracranial air
 Physical inability to wear the investigational device
(e.g. skin lesion on scalp, haematoma)
 Any other condition, which in the judgment of the
stroke clinician might prevent the patient from
tolerating CBA measurement or brain imaging (e.g.
severe agitation or requiring immediate intensive
treatment unit admission).
 Ambulance staff suspected stroke but hospital staff
do not consider that brain imaging within 60 min of
hospital arrival is a required investigation (e.g. a
different diagnosis is made with other routine
assessments or tests shortly after admission)
Participant identification and consent
Patients will be assessed for study suitability immediately
after arrival at the hospital in parallel with their urgent
clinical assessment. The regional ambulance service clin-
ical pathway mandates telephone pre-notification to hos-
pital during the conveyance of suspected stroke patients
with an onset time of less than 4 h. Upon arrival, the
stroke team will rapidly assess these patients including
the determinates of eligibility as listed above.
If the patient fulfils the eligibility criteria and staff
trained in the use of the CVS are in attendance, a CBA
measurement will subsequently be obtained following a
short verbal explanation. A formal research consent
process will not be undertaken at this point because
acute stroke treatments are time-dependent and patients
require a rapid assessment to avoid treatment delay. A
formal research consent process undertaken before the
CBA measurement would cause unacceptable delays.
The CBA measurement will be obtained whilst the
standard clinical assessment is ongoing.
Once the emergency assessment and treatments are com-
pleted, all patients who have had a CBA reading attempted
will be approached for study enrolment (including patients
where the CVS did not provide data due to technical difficul-
ties or where on review inclusion criteria were not met, e.g.
routine brain imaging had been intended but did not take
place for some reason).
Patients will be approached about study participation
by hospital research trained staff who will either have
been involved in CBA measurement or receive direct
communication from the clinical team about patients
who have undergone a measurement. Ideally, patients
will be approached during their inpatient stay such that
a timely discussion about the study can be held. How-
ever, some stroke and mimic patients are discharged
very early after attendance, including directly from the
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ED. Should a patient who underwent a CBA reading be
discharged from the hospital before the consent process
can be undertaken, a postal invitation to take part in the
study will be used.
Consent
The consent process will seek permission for retention
and analysis of CBA reading data and collection of se-
lected routinely recorded healthcare data related to acute
assessments and treatments (see ‘Study data collection’
section below) which are essential to complete the study
objectives. There are no additional study-specific
assessments.
Consent for patients who can be approached about study
participation during their inpatient stay
a) Consent for patients with mental capacity. For
eligible patients with the capacity to consent to
research, a research trained member of staff will
approach the patient to discuss the study and
provide a patient information sheet. After allowing
sufficient time for potential participants to decide
whether to take part in the study and an
opportunity to ask questions, consent will be
obtained in writing.
When a patient has mental capacity but is
unable to sign the consent form (e.g. because of
weakness of the dominant hand following
stroke), consent will be confirmed orally in the
presence of a witness (an individual not
otherwise involved in the trial) and the witness
will sign and date the consent form on behalf of
the participant.
b) Consent for patients with mild communication
difficulties. For patients with mild communication
difficulties due to the effects of stroke or a mimic
condition upon the use and understanding of language
(aphasia), a set of ‘easy access’ study documentation will
be used. After allowing sufficient time for the
information to be considered and an opportunity to ask
questions, consent will be obtained in writing using the
‘easy access’ consent form.
c) Consent for patients who lack mental capacity. It is
anticipated that approximately one-third of study eligible
patients will be unable to engage with an informed con-
sent process due to the effects of stroke and mimic con-
ditions upon communication and cognition. As
exclusion of this group would drastically reduce the clin-
ical relevance of the study, if a patient has been identified
as eligible but is unable to provide consent, a personal or
nominated (professional) consultee will be approached.
For potential participants who lack the capacity
to consent to research, a trained member of staff
will attempt to identify an appropriate personal
consultee (usually the next of kin) to approach,
discuss the study and provide a consultee
information sheet. If a personal consultee is
identified, after allowing sufficient time for him/
her to consider the patient’s wishes and feelings
and an opportunity to ask questions, the
consultee will be asked to complete a consultee
declaration form if they believe that the patient
would have no objection to taking part in the
study.
In the event of being unable to locate an
appropriate personal consultee before discharge, an
independent clinician (nominated consultee) will be
asked to confirm that the patient lacks capacity for
consent, and that study participation would not
introduce a risk of harm or be against the patient’s
wishes from what is known about their character
and beliefs. The independent clinician will sign a
nominated consultee declaration form concerning
study participation.
d) Consent and early mortality. The early mortality
rate following acute stroke is approximately 10%.
Some mimic conditions are also associated with
high mortality, e.g. severe infections. However, early
unexpected deaths also occur in both stroke and
mimic groups. Exclusion of patients who die soon
after admission would reduce the study’s relevance
for the typical suspected stroke population.
If a patient who underwent a CBA reading attempt
dies before consent can be obtained using one of
the approaches described above, the local principal
investigator will sign an early mortality declaration
form to confirm that the patient has died thus
taking responsibility for the use of data collected for
this research project.
Consent for patients who are discharged from hospital
Patients who are discharged from hospital before the
consent process can be undertaken will receive an invita-
tion letter, patient information sheet, consent form and
pre-paid return envelope by post. Patients willing to take
part in the study will be asked to return a completed
consent form. Invited patients who have not returned a
consent form within 4 weeks will receive one phone call
from the hospital research team to discuss the study.
Changes in capacity to consent to research during
participation in the study
As there are no additional study-specific assessments
and only collection of routinely available healthcare data
in this project after the CBA measurement, changes in
capacity status will not be reviewed.
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Consent not obtained
If a patient or a consultee declines the invitation to be in-
cluded in the study or does not return a postal consent
form, or if consent by one of the approaches above is not
obtained for any other reason, CBA measurement data
will be deleted. No further study data will be collected.
Figure 1 summarises the decision process for obtaining
study consent.
Cerebral Bioimpedance Asymmetry measurement process
(index test)
The Cerebrotech Visor System™ consists of two major
components: a scanner, worn like a pair of eyeglasses
over the forehead, and a ‘tablet’ computer, which serves
as the system’s controller and display. Within the scan-
ner, two radio emitter antennas are located at the back
of the head and a receiver antenna is positioned at the
forehead. No electrodes or metal come into direct con-
tact with the patient. Disposable sleeves cover the plastic
housing in contact with the patient to prevent skin con-
tamination between users. In addition, a cradle pillow
(with disposable sleeves) to be used for keeping the pa-
tient’s head centred and comfortable during the reading
is part of the CVS.
The scanner consists of electronic modules for gener-
ating radiofrequency waveforms, receiving the signals,
and performing associated operational functions. It also
has a rechargeable battery. The tablet running the
Fig. 1 Decision process for study consent
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monitoring software wirelessly controls the device
through a Bluetooth® connection and captures scan data.
During operation, the waveform generator supplies ra-
diofrequency signals to the emitter antennas and records
the signals acquired by the receiver antenna.
During a measurement, the tablet is turned on and the
CerebroScan™ software application is launched. The
scanner is switched on and placed on the patient’s head.
The CerebroScan interface screen has a click-box to
start the scan sequence, which is executed automatically.
Raw bioimpedance data are transmitted from the scan-
ner to the tablet. The patient wears the scanner for 2–3
min altogether. The operator subsequently removes the
scanner and turns off its power.
In order to create the numerical value for CBA (con-
tinuous data values 0–100), raw data from the CVS must
be further analysed by software held by the device
manufacturer (Cerebrotech Medical Systems Inc). Raw
data will be transmitted by the tablet to the manufac-
turer via the internet. These data are not identifiable as
each patient’s reading will be labelled with a unique
study ID only. Prior to transfer of data, CVS software
asks staff to confirm that patient consent is in place.
Only data where this is confirmed will be transmitted.
Data for non-consented patients will be deleted at this
point and not transferred. The manufacturer will return
the CBA reading to the researchers at Newcastle Univer-
sity Stroke Research Group who are leading the project.
At no point will the device reading be made available to
the hospital clinical team such that it could influence pa-
tient care. The device reading will similarly not be avail-
able to clinicians/researchers performing the brain
imaging review or attribution of reference standard out-
come states (see ‘Reference standard test (comparator)’
section below) until these data have been finalised. No
clinical data will be available to the manufacturer prior
to provision of a CBA reading.
Reference standards
Reference standard tests are required for key outcome
states which constitute the suspected stroke population:
large volume intracerebral haemorrhage (LICH), small/
medium intracerebral haemorrhage, ischaemic stroke
with LVO (LVO), ischaemic stroke without LVO, symp-
tomatic severe anterior vessel stenosis (SSAVS), transi-
ent ischaemic attack (TIA), mimic conditions and prior
territorial stroke (PTS). In clinical practice, some of the
acute outcome states can overlap (e.g ischaemic stroke
or TIA can be caused by SSAVS), and all acute outcome
states may co-exist with a prior territorial stroke. As
only one outcome state can be allocated for study ana-
lyses, non-overlapping discrete definitions and reference
standards have been assigned for each acute outcome
state and an attribution process developed to describe
when PTS will be the state assigned. The definitions and
attribution process result in the presence of any ‘com-
plex stroke’ (i.e. ischaemic stroke with LVO or SSAVS
or LICH ≥ 60 ml in volume or PTS) being dominant
over other states which are in keeping with the intended
purpose of the CVS test.
Whilst brain imaging tests are available which object-
ively confirm any intracerebral haemorrhage (CT), LVO
(CT/MR angiography), and PTS (CT), no single diagnos-
tic test exists for ischaemic stroke without LVO, SSAVS,
TIA and mimic conditions. For SSAVS, the reference
standard will be based on brain imaging plus clinical re-
port of the side of the body affected by focal neuro-
logical symptoms. For ischaemic stroke without LVO,
TIA and mimic conditions, the reference standards will
be based on expert clinician diagnosis informed by brain
imaging +/− other investigations as clinically appropri-
ate. Full details are given below and a summary of the
reference standards to be used is shown in Table 1.
Neuro-imaging defined outcome states
It is intended that all participants in this study will
undergo at least one brain-imaging test. According to
clinical indications, some participants will undergo
further imaging investigations. All imaging performed
within 72 h of admission will undergo blinded expert
review by an experienced neuro-radiologist. Where im-
aging alone is the reference standard test to determine
the presence of an outcome, the blinded review report(s)
will be used. Although local routine imaging reports will
also be obtained, these will not alter the data to be used
in the main study analyses. The frequency and nature of
any discrepancies between the reports will, however, be
reported on study completion.
Ischaemic stroke due to LVO will be defined as present if
CT or MR angiography has been conducted and demon-
strates reduced filling in any large branch of the anterior
cerebral circulation. This will be assessed and recorded by a
neuro-radiologist blinded to patient and study information
using the Ten Point Clot Burden Score [24]. A score < 10
will indicate presence of LVO. Angiography is not routinely
performed for all suspected stroke patients as clinical or
other radiological examination can preclude the need for the
investigation. It is routinely performed for participants where
plain CT has not shown a haemorrhage or another radio-
logical diagnosis for the acute symptoms, e.g. tumour.
Intracerebral haemorrhage will be defined as present if a
small (approximately < 30 ml), medium (approximately 30 to
< 60 ml) or large (approximately ≥ 60 ml) volume haema-
toma is recorded during CT (+/− MRI) review by a neuro-
radiologist blinded to patient and study information. The
haematoma volume will be estimated using the standard
ABC/2 formula where A is the greatest haemorrhage
diameter by CT, B is the diameter 90° to A, and C is
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the number of CT slices with haemorrhage multiplied
by the slice thickness (with approximate allowance for
any inter-slice gap) [25].
Prior territorial stroke will be defined as present if
an appropriate non-lacunar lesion of any size exists
on brain imaging in either cerebral hemisphere (i.e.
chronic hemispheric volume loss reflecting previous
non-lacunar infarction or ICH). If PTS is present,
the approximate proportion of volume loss in each
hemisphere will be recorded (< 24%; 25–49%; 50–
74%; > 74%).
Blinded review of images will also record the presence
of additional relevant features, e.g. interventricular
haemorrhage, subarachnoid haemorrhage, occlusion of
large posterior vessels (e.g. vertebral, basilar), cerebral/
cerebellar volume loss, but these features will not be
used to define outcome states.
SSAVS outcome state
SSAVS will be defined as present if (a) CT or MR angi-
ography has been conducted and this demonstrates that
there is ≥ 70% narrowing of any large branch of the an-
terior cerebral circulation (internal carotid artery or
middle cerebral artery) without occluding thrombus, (b)
the side of the focal neurological symptoms suffered by
the patient are in keeping with the imaging (e.g. the
stenosis is present in the circulation on the left and the
symptoms were on the right), and (c) the severity of the
focal symptoms is ≥ 6 on the NIHSS scale (measured on
admission).
Expert clinician diagnosis defined outcome states
As no single test exists for ischaemic stroke without
LVO, transient ischaemic attack (TIA) and mimic condi-
tions, expert clinician opinion informed by brain im-
aging +/− other investigations as appropriate will be
used as the reference standard.
An expert clinician diagnosis will be recorded for all
participants in this study although (as described above),
this will not be used to define the presence of LVO, in-
tracerebral haemorrhage, PTS or SSAVS outcomes.
Because primary medical diagnoses recorded in medical
records can vary according to the taxonomy used and the
terminology preferred by individual clinicians, e.g. chest in-
fection is synonymous with pneumonia, bronchopneumo-
nia and lower respiratory tract infection, clinicians will be
asked to select a ‘definite’ or ‘probable’ primary clinical
diagnosis according to a pre-defined framework as shown
in Table 2. As diagnoses are sometimes uncertain for a time
after admission to the hospital, clinicians will be asked to
provide a diagnosis assigned at 72 h after hospital admission
(or discharge/death if sooner). The framework will also in-
clude an option for ‘unclear’ if the clinician cannot assign a
diagnosis. If ‘unclear’ is selected, adjudication by two further
stroke team clinicians will be requested to attempt reso-
lution. If this is not possible, ‘unclear’ will still be recorded.
Ischaemic stroke without LVO will be defined as
present if the expert clinician considers the patient to
have a ‘definite’ or ‘probable’ ischaemic stroke, CT/MR
angiography confirms the absence of LVO (i.e. clot bur-
den score = 10), and CT/MR angiography plus clinical
findings confirm the absence of SSAVS.
Table 1 Summary of clinical outcome states and their reference standards
Outcome state Reference standard
Complex Ischaemic stroke with large vessel
occlusion
CT/MR angiography assessed by blinded neuro-radiologist. LVO defined as a Ten Point Clot Burden
Score <10.
Large volume intracerebral
haemorrhage
Brain imaging assessed by blinded neuro-radiologist. Haematoma volume of at least 60ml in a single
cerebral hemisphere.
Prior territorial stroke Brain imaging assessed by blinded neuro-radiologist. Appropriate changes in either cerebral
hemisphere.
Symptomatic severe anterior
vessel stenosis
CT/MR angiography assessed by blinded neuro-radiologist which shows ≥ 70% narrowing of any
large branch of the anterior cerebral circulation (ICA or MCA) without occluding thrombus, the side of
the focal neurological symptoms suffered by the patient is compatible with stenosis, the severity of
focal symptoms is ≥ 6 on NIHSS.
Minor
Stroke
Small / medium volume
intracerebral haemorrhage
Brain imaging assessed by blinded neuro-radiologist. Haematoma volume < 60ml in a single cerebral
hemisphere.
Ischaemic stroke without large
vessel occlusion
Expert clinician diagnosis at 72 hours after hospital admission (or discharge/death if sooner), CTA/
MRA confirms the absence of LVO (i.e. Clot Burden Score = 10), and CTA/MRA plus clinical findings
confirm the absence of SSAVS.
Non
Stroke
Transient ischaemic attack Expert clinician diagnosis at 72 hours after hospital admission (or discharge/death if sooner) and brain
imaging findings do not refute the clinician opinion or indicate the presence of one of the other
acute outcomes.
Mimic condition Expert clinician diagnosis at 72 hours after hospital admission (or discharge/death if sooner) and brain
imaging findings do not refute the clinician opinion or indicate the presence of one of the other
acute outcomes.
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Table 2 Pre-defined primary diagnosis framework
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Table 2 Pre-defined primary diagnosis framework (Continued)
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Table 2 Pre-defined primary diagnosis framework (Continued)
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It is possible that there will be participants with a clinical
diagnosis of ischaemic stroke who do not undergo CT/
MR angiography for some reason (e.g. due to agitation). In
these cases, the LVO and SSAVS status are unknown.
Data from these participants will not be included in any
analysis of operating characteristics but their clinical and
radiological information and CBA data will still be
reported.
A transient ischaemic attack will be defined as present
if the clinician records any ‘definite’ or ‘probable’ TIA
diagnosis using the pre-defined framework and brain im-
aging does not contain findings that refute this opinion
or indicate the presence of one of the other acute
outcomes. If there is any disagreement between the
blinded neuro-radiological review of imaging performed
and a clinical diagnosis of TIA, the imaging diagnosis
will be used to determine the outcome but such discrep-
ancies will also be reported.
A stroke mimic condition will be defined as present if
the clinician records any ‘definite’ or ‘probable’ non-
stroke/non-TIA diagnosis using the pre-defined frame-
work and brain imaging is compatible (e.g. tumour) plus
does not contain findings which indicate the presence of
one of the other acute outcomes. If there is any disagree-
ment between the blinded neuro-radiological review of
imaging performed and a clinical diagnosis of mimic
Fig. 2 Decision tree for assigning the outcome state to be used in the main study analyses
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condition, the imaging diagnosis will be used to determine
the outcome but such discrepancies will also be reported.
If a clinician records an ‘unclear’ diagnosis for any pa-
tient and this cannot be resolved, these participants will
not be included in any analyses of operating characteris-
tics as it has not been possible to determine an outcome.
Available data for these participants will still be reported.
Outcome state attribution process
Participants with a clinical diagnosis of ischaemic stroke
who have not had a CTA/MRA conducted will not have
an outcome state attributed because their LVO or SSAVS
status cannot be established. Where participants have evi-
dence (as described by the reference standards above) of a
new LVO, LICH or SSAVS, these will be the outcome
states assigned. For other participants, if PTS is present ir-
respective of other outcome states, PTS will be assigned.
Where participants do not have PTS, they will be assigned
small/medium intracerebral haemorrhage, ischaemic
stroke without LVO, TIA or mimic condition according
to the reference standard criteria described above. The at-
tribution process is illustrated as a decision tree in Fig. 2.
Study data collection
For patients who give consent for enrolment in the study,
CBA measurement data, imaging data and routine health-
care data to confirm study eligibility and conduct study
analyses will be collected. CBA measurement data will be
captured by the CVS device and subsequently harvested
to be linked with clinical data. The CBA measurement
process, imaging data and other routine healthcare will be
recorded onto study-specific case record forms by hospital
staff trained to deliver this research project.
Data from case record forms will be entered locally
onto a secure online database maintained by Newcastle
University Stroke Research Group. Participants will be
identified by a unique study number only in both the
paper case record form and study database. Where con-
sent is not obtained, case record form data recorded
about the CBA measurement process (which took place
prior to consent) will be destroyed and not uploaded
onto the online database. As detailed in ‘Cerebral Bioim-
pedance Asymmetry measurement process (index test)’
section above, data from the CVS device will be deleted.
Data about the CBA measurement process
Date/time of attempted CBA measurement; location of
CBA measurement attempt (accident/emergency depart-
ment/medical admissions unit/acute stroke unit/CT scan
room/other); patient head position during CBA reading
(CBA cradle used/hospital pillow used/both cradle and
hospital pillow used/no head support used/other); angle
of the head of the bed during CBA measurement (15 °/30
°/45 °/60 °/unknown); CBA data obtained (yes/no); if data
was obtained, any pertinent events which took place dur-
ing the reading (e.g. sneezing, coughing, head tilting); if
data were not obtained, reason why abandoned (patient
agitation/insufficient time before brain imaging/change in
condition of the patient/scanner or tablet malfunction/
other); complications from CBA measurement (yes: skin
irritation; injury; corneal abrasion; other free text/no)
Data related to the first 24 h of admission
Data for confirmation of inclusion and exclusion criteria:
Demographic information (age); date/time of hos-
pital attendance; confirmation of admission by ambu-
lance (yes/no); confirmation that ambulance personnel
suspected stroke (yes/no); symptom onset or last
known to be well date/time (hospital judgement); first
recorded conscious level on arrival at hospital (AVPU
scale); first blood glucose reading on admission (capil-
lary or serum glucose); confirmation of other inclu-
sion and exclusion criteria (e.g. brain imaging will be
performed, absence of electro-stimulating devices in
the head and neck).
Other data related to day 1 of admission:
Demographic information (gender); symptoms sug-
gesting possible stroke according to the ambulance
clinician (facial weakness; arm weakness; speech disturb-
ance; other); side of symptoms according to the ambu-
lance clinician (left/right/both/not applicable, e.g.
speech); first blood pressure reading on admission; first
heart rate reading on admission; first body temperature
reading on admission; first peripheral oxygen saturation
on admission; ECG rhythm (presence of atrial fibrilla-
tion); stroke symptom severity as soon as possible after
arrival (National Institute of Health Stroke Score
(NIHSS) including all component scores [7]); time of
NIHSS completion; clinical stroke type according to new
symptoms (Oxford Community Stroke Project classifica-
tion including left/right lateralisation as appropriate
[26]); previous medical history from healthcare records
(stroke; head injury; intracranial surgery; TIA; atrial fib-
rillation; diabetes; hypertension; hyperlipidaemia); if a
previous stroke was recorded, had it resulted in perman-
ent arm or leg weakness (no; yes left; yes right; yes both),
or any permanent speech difficulty (yes or no); current
use of anticoagulant medication; pre-stroke modified
Rankin Score [27]; pre-stroke walking ability (independ-
ent; walking aid; physical assistance from one person;
unable to walk at all); diagnosis listed after completion
of initial assessments (stroke/non-stroke (if non-stroke
free text for diagnosis); thrombolysis treatment adminis-
tered (yes/no); date/time of bolus administration (if
thrombolysis received); mechanical thrombectomy treat-
ment administered (yes/no); date/time of arterial punc-
ture (if thrombectomy received).
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Data related to 72 h after admission (or death/discharge if
this is sooner)
Deceased, inpatient or discharged alive at 72 h after ad-
mission; if deceased, cause of death according to death
certificate; if discharged/deceased, discharge/death date;
confirmation that symptom onset time recorded in data
related to first 24 h of admission is still correct at 72 h
after admission or death/discharge if sooner (yes/no, if
no, new date/time); primary medical diagnosis in place
at 72 h after admission or death/discharge if sooner, re-
corded according to the pre-defined framework (see
‘Reference standard test (comparator’ section above);
new complication of CBA measurement documented by
72 h after admission or death/discharge if sooner (yes:
skin irritation; injury; corneal abrasion; infection; other
free text/no); follow-up information about any complica-
tion previously noted (free text).
Imaging data
Brain imaging performed in the first 72 h of attendance (CT/
MR/CTangiograpy /MRangiography/none); brain imaging
date(s) and time(s); brain imaging result(s) (formal report/
documentation in the medical records if no formal report
plus selection of infarction, haemorrhage or other); for par-
ticipants with a diagnosis of ischaemic stroke at 72 h (or
death/discharge if sooner): CT or MR angiography per-
formed on admission (yes/no); for ischaemic stroke without
angiography: reason why angiography was not performed
(stroke too mild/plain CT imaging changes too advanced/pa-
tient clinically unsuitable for thrombectomy: state reason/
thrombectomy unavailable in time for treatment/other)
Anonymised brain images will also undergo separate
blinded neuro-radiologist review using a standard check-
list to record: changes of cerebral ischaemia including
Alberta Stroke Program Early CT Score (ASPECTS)
score [28]; haemorrhage including approximate haema-
toma size using the ABC/2 approach [25]; prior territor-
ial stroke in either cerebral hemisphere (occupying <
24%; 25%–49%; 50%–74%; > 74% on each side); other
pathological findings (e.g. subdural haematomas, tu-
mours, subarachnoid blood).
If angiography is performed, the following will also be
recorded: Ten-Point clot burden score [24]; extended
thrombolysis in cerebral infarction scale [29]; absence/
presence of anterior vessel stenosis and approximate per-
cent of maximal luminal narrowing (< 50%; 50–69%; 70–
99%; 100%); approximate ASPECTS Collateral Score (an
approximation because no additional imaging sequences
will be done specifically to examine collateral flow) [30].
Blinding
Patients, clinicians and hospital research staff will be
blinded to CBA results. Neuro-radiologists responsible
for providing the independent imaging reports and
research clinicians responsible for the outcome state at-
tribution process will also be blinded to CBA results. In
addition, staff from Cerebrotech Medical Systems Inc
who will provide CBA readings from raw measurement
data will not have access to any clinical data prior to
provision of a CBA reading.
Staff training and awareness
Study-specific training will be provided for stroke clini-
cians and hospital research staff. This will cover participant
identification, use of the CVS, consent, and completion of
the study documentation and database as appropriate.
Study withdrawal
No specific withdrawal criteria have been pre-set. Partic-
ipants may withdraw from the study at any time for any
reason. Data collected prior to withdrawal will be used
in the study analysis unless the patient or their represen-
tative requests that this should not be the case. Should a
decision to withdraw from the study be made, a reason
for withdrawal will be sought but participants can
choose to withdraw without providing an explanation.
Safety evaluation
This is a clinician-blinded observational study of a CE-
marked diagnostic technology that has already been used
in a clinical setting and will not change patient treat-
ment. The risks from participation should be no greater
than standard clinical care. The measurement of CBA
takes less than 3 min and occurs in parallel with the
clinical assessment process, so will not cause any mean-
ingful delay in the provision of standard care.
There are no known complications following exposure
to low-energy electromagnetic fields. During the assess-
ment, there is brief superficial contact between patients
and the portable CVS device, which itself does not con-
tain any biological or hazardous materials. Any risk of
cross-infection is eliminated by a disposable sleeve cov-
ering wherever the frame of the scanner is in contact
with the patient’s skin. No safety issues were reported
during proof of concept studies in North American hos-
pital and ambulatory settings (n = 235), which specific-
ally sought evidence of skin irritation, injury, infection
and corneal abrasion [21].
Study data collection will include documentation of
any complications following the immediate use of the
device. Follow-up information about any such complica-
tions will be sought at 72 h after admission. Additionally,
routine data collection will include a check for any new
complications by 72 h after admission.
Should a medical event occur which is serious (results in
death; is life-threatening; requires inpatient hospitalisation or
prolongation of existing hospitalisation; results in persistent
or significant disability or incapacity; consists of a congenital
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anomaly or birth defect; otherwise considered significant by
investigator) and is perceived to be related to the use of the
CVS, a separate study Serious Adverse Event form will be
completed. All such events will be considered ‘unexpected’
and reported to the chief investigator, study sponsor and Re-
search Ethics Committee.
Statistical analysis
1. Objective 1: To determine the diagnostic accuracy
of CBA measurement performed using the CVS to
identify complex stroke (ischaemic stroke with LVO
or SSAVS or LICH ≥ 60 ml in volume or PTS) in
patients arriving at the hospital with a paramedic
assigned diagnosis of suspected acute stroke.
In the recently published work using this technol-
ogy, a threshold of CBA = 10 was derived as optimal
for identification of complex stroke [21]. This thresh-
old will be validated on the data collected in this
study and considered acceptable if it results in specifi-
city of at least 80% and sensitivity of at least 70%.
These values have been chosen as clinically important
and stringent, to allow validation to be conducted.
Sensitivity and specificity will be reported with 95%
confidence intervals.
However, the population to be recruited in this study
may differ from the earlier work (e.g. less time has
elapsed since stroke onset). Therefore, the threshold of
CBA = 10 may not result in meeting the criteria de-
scribed above. If this is the case, a new threshold will be
estimated. Univariate logistic regression analysis with
diagnosis (complex stroke) as the outcome (y) and CBA
measurement as the explanatory variable (x) will be used
to construct an empirical receiver operating characteris-
tic (ROC) curve for all possible thresholds. A new
threshold will be chosen to maximize specificity while
aiming to maintain a clinically acceptable level of sensi-
tivity (70% in this instance). Sensitivity, specificity and
ROC area under curve (AUC) (with confidence intervals)
will be reported for the chosen threshold.
2. Objective 2: To determine the diagnostic accuracy
of CBA measurement performed using the CVS to
identify LVO in patients arriving at the hospital
with a paramedic assigned diagnosis of suspected
acute stroke.
For this objective, analyses as described above for ob-
jective 1 will be conducted, i.e. a threshold of CBA = 10
will initially be evaluated but a new threshold may be es-
timated if CBA = 10 does not result in sensitivity and
specificity meeting the stated criteria.
3. Objective 3: To explore key clinical and radiological
influences upon the diagnostic accuracy of CBA
measurement for complex stroke and LVO.
This is an exploratory objective, and as such the ana-
lyses will be data-driven and dependent on results for
objectives 1 and 2. Proposed investigations focus on
three main areas: (i) whether available clinical data
might be incorporated to improve the diagnostic accur-
acy of the CVS; (ii) variations in specification of the ref-
erence diagnosis for LVO, and (iii) patient subgroup
analyses to identify whether the CVS may perform better
in some clinical settings than others.
(i) Clinical covariates: key variables will be added to the
logistic regression models described in objectives 1 and
2 to see if this could significantly increase the accuracy
of the prediction of the model. Clinical variables that
would be available to ambulance personnel or staff
involved in urgent assessment at the hospital will be
included to reflect those available at the point of
testing. Multivariate logistic regression will be
conducted, with diagnosis (complex stroke OR LVO)
as the outcome (y) and CBA measurement along with
variables considered to be of possible clinical
importance (such as gender, age, NIHSS) as the
explanatory variables (x1, x2, x3,…). A stepwise
variable selection procedure will be used, and only
variables that significantly improve the ROC AUC will
be retained in the model. Sensitivity, specificity, ROC
AUC (with confidence intervals) and threshold will be
reported if a suitable model is found.
(ii) Alternative definitions for LVO: the diagnostic
accuracy of CBA measurement will be assessed by
modelling as described for objective 1, where the
reference diagnosis will be assigned as follows:
 Radiological definition: At the time of the data
analysis, if the clinical consensus regarding size and
distribution of clot that is feasible for
thrombectomy (described using the clot burden
score and/or the extended TICI scale) has changed,
the alternative definition(s) will be used to re-
categorise participants as LVO present or absent.
 Best clinical standard for LVO identification:
currently, the most accurate clinical scale for the
indication of the presence of LVO is the Rapid
Arterial oCclusion Evaluation (RACE) [31]. A
numerical RACE score will be calculated
retrospectively using the hospital NIHSS (which
contains all score items), as RACE is not
routinely in use in the UK and will not be used
in this study. RACE scores will be used to re-
categorise participants as LVO present or absent
based upon a published cut-off value.
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(iii)Exploratory subgroup analysis: if data permit, this will
be carried out by graphical presentation of the CBA
results. The proposed subgroups to investigate are:
 Acute stroke: patients with a diagnosis of acute
stroke will be evaluated (i.e. after exclusion of
patients with PTS, TIA and mimic conditions).
 Acute IS: patients with acute ischaemic stroke will
be evaluated (i.e. after exclusion of patients with
TIA, mimic conditions, PTS and haemorrhage).
 Exclusion of participants having posterior circulation
stroke: participants with posterior circulation stroke,
defined by the Oxford Community Stroke Project
(OCSP) classification and verified against relevant
NIHSS components will be excluded. Clinically,
these individuals would be considered unlikely to
have anterior circulation vessel occlusion or
haemorrhage, and might not have a CBA reading
performed as part of their emergency assessment.
The remaining population will be evaluated.
Further exploratory analyses may be undertaken but
these analyses will be data-driven and reported as such.
4. Objective 4: To report the technical failure rate of
the CVS.
Technical and clinical reasons will be reported for
why a CBA reading was attempted but not obtained.
Technical reasons will include device failure resulting
in no data acquisition, and collection of erroneous
raw data leading to calculation of a CBA value which
is perceived to have an implausible bioimpedance
pattern.
Data from the following groups will be reported but
excluded from the analyses:
a. Participants with ischaemic stroke but without CT
angiography or MR angiography, as their LVO state
is unknown.
b. Participants with an expert clinician diagnosis of
‘unclear’ which cannot be resolved as it has not
been possible to assign a diagnosis.
c. Following attendance at the hospital, other
information sources may reveal retrospectively that
one or more of the study eligibility criteria have not
been met (e.g. the symptom onset was more than 6
h ago). This is not uncommon during emergency
care assessments due to the accuracy of information
immediately available. Participants who do not meet
the inclusion criteria according to information
available by 72 h after admission will not contribute
towards the analyses.
d. Participants where a CBA reading is attempted but
this is unsuccessful (the CVS alerts the operator to
failure to capture data).
e. All CBA readings obtained will be checked for a
plausible bioimpedance pattern. Participants with
CBA readings who are perceived to be implausible
will not be included in the analyses, e.g. readings
obtained from patients with previously unknown
cranial metallic implants.
Sample size
The future intended purpose of CBA measurement is
to ‘rule in’ patients with complex stroke and/or LVO
from the suspected stroke population. The sample
size calculation is therefore based on the detection of
test specificity. ‘Rule in’ is chosen as the test results
would be used to redirect individuals to a neurosci-
ence centre for highly specialist care. Suspected stroke
patients without a diagnosis of complex stroke or
LVO do not need transportation to a neuroscience
centre and should be admitted to the nearest local
hospital.
Reported frequencies for LVO, large intracerebral
haemorrhages and prior territorial stroke are 27%,
3% and 4% respectively amongst the unselected
population with suspected stroke. There are no reli-
able estimates for the frequency of SSAVS in the un-
selected UK population—it is an uncommon finding
and previous cohorts of LVO patients are likely to
have included cases with high degrees of symptom-
atic stenosis without reporting them separately.
Therefore, using the above-reported frequencies and
a minimum specificity of 70% from the diagnostic
test, alpha = 0.05 and beta = 0.1:
– One hundred twelve participants would detect a
specificity of 85% (95%CI: 70%–100%) for complex
stroke (i.e. LVO + SSAVS + LICH + PTS) versus all
other outcomes in the suspected stroke population (i.e.
small/medium intracerebral haemorrhage + ischaemic
stroke without LVO + TIA + mimic condition).
– One hundred one participants would detect a
specificity of 85% (95%CI: 70%–100%) for ischaemic
stroke due to LVO versus all other outcomes in the
suspected stroke population (i.e. SSAVS + LICH +
PTS + small/medium intracerebral haemorrhage +
ischaemic stroke without LVO + TIA + mimic
condition).
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In terms of sensitivity, the 112 participants would de-
tect sensitivity of 85% (95%CI: 63%–100%) for complex
stroke and 85% (95%CI: 61%–100%) for LVO.
As outlined above, some enrolled participants may not
provide data for inclusion in the analyses and this lack of
data is difficult to estimate. The initial recruitment target
is inflated for 10% data exclusion (124 participants) but
prospective monitoring of the number of cases which can
contribute to the analyses will occur and fewer or add-
itional participants will be sought if required.
Study monitoring, quality control and quality assurance
The Chief Investigator will have overall responsibility
for study conduct. The local Principal Investigator
will be responsible for the day-to-day study conduct
at the NHS site. The study will be managed by a co-
ordinating centre based at Newcastle University
Stroke Research Group who will provide training
and day-to-day support for the NHS site. Quality
control will be maintained through adherence to
Newcastle Biomedicine Clinical Research Platform
SOPs, the study protocol and research governance
regulations. The study may be subject to inspection
and audit by Newcastle upon Tyne Hospitals NHS
Foundation Trust under their remit as sponsor.
Dissemination of results
The study will be presented at national and international
conferences and reported in peer-reviewed journals. Re-
ports will be written for the study funder, sponsor and
regulatory bodies. A lay summary of the results will be
available for study participants.
Discussion
There is substantial high-quality evidence that early ac-
cess to thrombolysis, thrombectomy and specialist care
improve stroke outcomes. However, stratification of pa-
tients with suspected stroke is challenging and this can
lead to delays to care. Cerebral Bioimpedance Asym-
metry measurement using the Cerebrotech Visor™ Sys-
tem may enable rapid identification of certain stroke
types that benefit from time-critical treatment. In par-
ticular, a quick and portable test for LVO could signifi-
cantly improve access to thrombectomy with subsequent
improved outcome improved outcome from this stroke
type. This study will provide data about the diagnostic
accuracy of CBA measurement for LVO and other types
of complex stroke.
Study status
At the time of submission of this manuscript, the study
is in setup. Recruitment is scheduled to commence in
October 2019. Protocol version 3 dated 11th May 2019
was used to prepare this manuscript.
Abbreviations
ASPECTS: Alberta Stroke Program Early CT ScoreAUCArea under
curveAVPUAlert Voice Pain UnresponsiveCBACerebral Bioimpedance
AsymmetryCTComputerised tomographyCVSCerebrotech Visor™
SystemHASUHyperacute stroke unitISRCTNInternational Standard
Randomised Controlled Trials NumberLICHLarge volume intracerebral
haemorrhageLVOLarge vessel occlusionMRIMagnetic resonance
imagingNHSNational Health ServiceNIHSSNational Institute of Health Stroke
ScalePTSPrior territorial strokeROCReceiver Operating
CharacteristicSSAVSSymptomatic severe anterior vessel
stenosisSTARDStandards for the Reporting of Diagnostic accuracy
studiesTIATransient ischaemic attack
Acknowledgements
Not applicable
Authors’ contributions
CP, LS, AD, SG, DM, HR and PW prepared the grant application and secured
funding. CP and LS led the development of the study protocol, obtained
ethical approval and will lead delivery of the project. PW, DM, AD and HR
contributed to clinical and radiological assessment sections of the protocol
relevant to their particular expertise. PW and DM are providing radiological
adjudication expertise. AD and HR will provide expert assistance for clinical
adjudication as required. LSu is providing study and data management. SG
and CL provide methodological and statistical support. All authors read and
approved the final manuscript.
Funding
This project is funded by the Medical Research Council Confidence in
Concept scheme and CVS visors are provided free of charge from
Cerebrotech Medical Systems Inc, San Francisco USA. Authors SG and CL are
supported by funding from the National Institute for Health Research (NIHR).
Staff from Cerebrotech Medical Systems Inc, advised on aspects of study
design. The Medical Research Council had no role in study design.
Availability of data and materials
Not applicable.
Ethics approval and consent to participate
Ethical (National Research Ethics Service Committee North East - Newcastle &
North Tyneside 1, reference: 18/NE/0219) and NHS approvals have been
granted. Written informed consent is obtained for patient participation as
detailed above.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1Stroke Research Group, Population Health Sciences Institute, Newcastle
University, Henry Wellcome Building, Framlington Place, Newcastle upon
Tyne NE2 4HH, UK. 2Newcastle upon Tyne Hospitals NHS Foundation Trust,
Royal Victoria Hospital, Queen Victoria Road, Newcastle upon Tyne NE1 4LP,
UK. 3NIHR Newcastle In Vitro Diagnostics Co-operative, Room M2.061, William
Leech Building, Medical School, Newcastle University, Framlington Place,
Newcastle upon Tyne NE2 4HH, UK.
Received: 20 August 2019 Accepted: 28 November 2019
References
1. Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M,
Bennett DA, et al. Global and regional burden of stroke during 1990-
2010: findings from the Global Burden of Disease Study 2010. Lancet.
2014;383(9913):245–54.
Price et al. Diagnostic and Prognostic Research             (2020) 4:2 Page 17 of 18
2. National Audit Office. Reducing brain damage: faster access to better stroke
care. London 2005.
3. Stroke Unit Trialists Collaboration. Organised inpatient (stroke unit) care for
stroke. Cochrane Database Syst Rev. 2013:CD000197.
4. Wardlaw JM, Murray V, Berge E, Del Zoppo GJ. Thrombolysis for acute
ischaemic stroke. Cochrane Database Syst Rev. 2014;CD000213.
5. National Institute for Health and Care Excellence. Alteplase for treating
acute ischaemic stroke (review of technology appraisal guidance 122): NICE
technology appraisal guidance 264 2012.
6. Saver JL, Goyal M, van der Lugt A, Menon BK, Majoie CB, Dippel DW, et al.
Time to Treatment With Endovascular Thrombectomy and Outcomes From
Ischemic Stroke: A Meta-analysis. JAMA. 2016;316(12):1279–88.
7. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, et al.
Measurements of acute cerebral infarction: a clinical examination scale.
Stroke. 1989;20(7):864–70.
8. Intercollegiate Stroke Working Party. National Clinical Guideline for Stroke
5th Edition. Royal College of Physicians. 2016.
9. Powers WJ, et al. 2018 Guidelines for the early management of patients
with acute ischemic stroke: a guideline for healthcare professionals from the
American Heart Association/American Stroke Association. Stroke. 2018;
https://doi.org/10.1161/STR.0000000000000158.
10. Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, et al.
Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit
and Infarct. New England Journal of Medicine. 2018;378(1):11–21.
11. Smith WS, Lev MH, English JD, Camargo EC, Chou M, Johnston SC, et al.
Significance of large vessel intracranial occlusion causing acute ischemic
stroke and TIA. Stroke. 2009;40(12):3834–40.
12. Tawil SE, Cheripelli B, Huang X, Moreton F, Kalladka D, MacDougal NJJ, et al.
How many stroke patients might be eligible for mechanical thrombectomy?
European Stroke Journal. 2016;1(4):264–71.
13. Clinical Effectiveness and Evaluation Unit Royal College of Physicians. The
Sentinel Stroke National Audit Programme (SSNAP). https://www.rcplondon.
ac.uk/projects/ssnap-clinical-audit.
14. Mohamad NF, Hastrup S, Rasmussen M, Andersen MS, Johnsen SP,
Andersen G, et al. Bypassing primary stroke centre reduces delay and
improves outcomes for patients with large vessel occlusion. European
Stroke Journal. 2016;1(2):85–92.
15. Turc G, Maier B, Naggara O, Seners P, Isabel C, Tisserand M, et al. Clinical
Scales do not reliably identify acute ischemic stroke patients with large-
artery occlusion. Stroke. 2016;47(6):1466–72.
16. Carvalho M, Oliveira A, Azevedo E, Bastos-Leite AJ. Intracranial arterial
stenosis. Journal of Stroke & Cerebrovascular Diseases. 2014;23(4):599–609.
17. Salihović D, Smajlović D, Ibrahimagić O. Does the volume and localization of
intracerebral hematoma affect short-term prognosis of patients with
intracerebral hemorrhage. ISRN Neuroscience,. 2013;doi:10.1155/2013/327968.
18. Hemphill JC 3rd, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman
M, et al. Guidelines for the management of spontaneous intracerebral
hemorrhage: a guideline for healthcare professionals from the American Heart
Association/American Stroke Association. Stroke. 2015;46(7):2032–60.
19. Gonzalez C, Rubinsky B. Frequency dependence of phase shift in edema: a
theoretical study with magnetic induction. Conf Proc IEEE Eng Med Biol
Soc. 2005;4:3518–21.
20. Gonzalez CA, Valencia JA, Mora A, Gonzalez F, Velasco B, Porras MA, et al.
Volumetric electromagnetic phase-shift spectroscopy of brain edema and
hematoma. PLoS One. 2013;8(5):e63223.
21. Kellner C, Sauvageau E, Snyder K, et al. The VITAL Study and Overall Pooled
Analysis with the VIPS Non-Invasive Stroke Detection Device. J Neurointerv
Surg. 2018;10(11):1079–84.
22. McClelland G, Rodgers H, Flynn D, Price CI. The frequency, characteristics
and aetiology of stroke mimic presentations: a narrative review. European
Journal of Emergency Medicine. 2019;26(1):2–8.
23. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al.
STARD 2015: an updated list of essential items for reporting diagnostic
accuracy studies. BMJ. 2015;351:h5527.
24. Puetz V, Dzialowski I, Hill MD, Subramaniam S, Sylaja PN, Krol A, et al.
Intracranial thrombus extent predicts clinical outcome, final infarct size and
hemorrhagic transformation in ischemic stroke: the clot burden score. Int J
Stroke. 2008;3(4):230–6.
25. Kothari RU, Brott T, Broderick JP, Barsan WG, Sauerbeck LR, Zuccarello M,
et al. The ABCs of measuring intracerebral hemorrhage volumes. Stroke.
1996;27(8):1304–5.
26. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and
natural history of clinically identifiable subtypes of cerebral infarction.
Lancet. 1991;337(8756):1521–6.
27. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J.
Interobserver agreement for the assessment of handicap in stroke patients.
Stroke. 1988;19(5):604–7.
28. Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a
quantitative computed tomography score in predicting outcome of
hyperacute stroke before thrombolytic therapy. ASPECTS Study Group.
Alberta Stroke Programme Early CT Score. Lancet. 2000;355(9216):1670–4.
29. Goyal M, Fargen KM, Turk AS, Mocco J, Liebeskind DS, Frei D, et al. 2C or
not 2C: defining an improved revascularization grading scale and the need
for standardization of angiography outcomes in stroke trials. J Neurointerv
Surg. 2014;6(2):83–6.
30. Menon BK, Smith EE, Modi J, Patel SK, Bhatia R, Watson TW, et al. Regional
leptomeningeal score on CT angiography predicts clinical and imaging
outcomes in patients with acute anterior circulation occlusions. American
Journal of Neuroradiology. 2011;32(9):1640–5.
31. Perez de la Ossa N, Carrera D, Gorchs M, Querol M, Millan M, Gomis M,
et al. Design and validation of a prehospital stroke scale to predict
large arterial occlusion: the rapid arterial occlusion evaluation scale.
Stroke. 2014;45(1):87–91.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Price et al. Diagnostic and Prognostic Research             (2020) 4:2 Page 18 of 18
